CURRICULUM VITAE Dr. Philip F. Halloran

Dr. Philip F. Halloran is a clinician-scientist whose research focus is organ transplantation and organ diseases, at the clinical and basic levels. He received his MD and internal medicine/nephrology (FRCPC) from the University of Toronto and his PhD from the University of London. He was a professor of medicine at the University of Toronto before joining the University of Alberta, where he was director of the division of nephrology and transplantation for 15 years. Dr Halloran then developed the Alberta Transplant Applied Genomics Centre (ATAGC) (<https://www.ualberta.ca/medicine/institutes-centres-groups/atagc>), now the world’s leading centre for molecular studies of organ transplants, based on human biopsies and experimental models. He has published 350 peer reviewed papers.

His research has focussed on the mechanisms of tissue injury and inflammation, particularly at the level of changes in gene expression, using organ transplants as the principal model. A particular interest has been antibody-mediated kidney rejection, now recognized as the leading cause of late kidney transplant loss. He has also been an investigator in many clinical trials of immunosuppressive agents. His recent focus has been to develop diagnostic applications of the molecular changes in human diseases, and their relationship to the clinical and histologic findings. The goal is to understand human disease states, learning the lessons in organ transplant biopsies and applying those lessons in primary organ diseases. A key element in this is the development of a Molecular Microscope® Diagnostic System (MMDx) that uses microarrays to read human biopsies.

He was the founding editor-in-chief of the world’s leading transplantation journal, the American Journal of Transplantation, with the editorial office at the U of A from 2000 to 2010. He was also the founding Chairman of the Board of Trustees of the Roche Organ Transplant Research Foundation, a Swiss based charity. He is an Officer of the Order of Canada, a Fellow of the Royal Society of Canada, and an elected member of the American Society of Clinical Investigation. He received the 2016 Prix Galien Canada Research Award, 2016 Doctor Honoris Causa Award presented by the Faculté de médecine de l’Université de Paris Descartes and the 2018 J. Gordin Kaplan Award for Excellence in Research from the University of Alberta. He has trained and mentored many clinician-scientists who are now key opinion leaders internationally.

**Publications (2016-present)**

1. Venner JM, Famulski KS, Reeve J, Chang J, **Halloran PF**. Relationships among injury, fibrosis, and time in human kidney transplants. JCI Insight 2016;1(1):e85323.

2. **Halloran PF**, Famulski KS, Reeve J. Molecular assessment of disease states in kidney transplant biopsies. Nature Reviews Nephrology 2016; doi:10.1038/nrneph.2016.85. 12(9):534-48

3. Falk JA, Cardella CJ, **Halloran PF**, Robinette M, Arbus G, Bear R. Transplantation can be performed with positive (noncurrent) crossmatch. Transplant Proc 2016;17:1530-2.

4. **Halloran PF**, Famulski KS, Chang J. A probabilistic approach to histologic diagnosis of antibody-mediated rejection in kidney transplant biopsies. Am J Transplant 2017;(1):129-139.

5. Einecke G, Reeve J and **Halloran PF**. Hyalinosis lesions in renal transplant biopsies: interpretation depends on TxBx interval. Am J Transplant 2017;17(5):1346-57.

6. Parkes MD, **Halloran PF** and Hidalgo LG. Evidence for CD16a-mediated NK cell stimulation in antibody-mediated kidney transplant rejection. Transplantation 2017;101:e102-e111.

7. Loupy A, Duong Van Huyen JP, Hildalgo LG, Reeve J, Racape M, Venner JM, Famulski KS, Bories MC, Beauscart T, Guillemain R, Francois A, Pattier S, Toquet C, Gay A, Rouvier P, Varnous S, Leprince P, Empana JP, Lefaucheur C, Bruneval P, Jouven X and **Halloran PF**. Gene Expression Profiling for the Identification and Classification of Antibody-Mediated Heart Rejection. Circulation 2017;135:917-935.

8. **Halloran PF**, Venner JM and Famulski KS. Comprehensive analysis of transcript changes associated with allograft rejection: Combining universal and selective features. Am J Transplant 2017;17(7):1754-69.

9. Parkes MD, **Halloran PF**, Hidalgo LG. Direct evidence for CD16a-mediated NK cell stimulation in antibody-mediated kidney transplant rejection. Transplant 2017;101(4):e102-e111.

10. Madill-Thomsen K, Wiggins R, Eskandary F, Bohmig G, **Halloran PF**.  The effect of cortex/medulla proportions on molecular diagnoses in kidney transplant biopsies: rejection and injury can be assessed in medulla. Am J Transplant 2017 Feb 22;17(8):2117-28.

11. **Halloran PF**, Akalin E, Aubert O, Bohmig G, Brennan D, Bromberg J, Einecke G, Eskandary F, Gosset C, Duong Van Huyen J-P., Gupta G, Lefaucheur C, Malone A, Seron D, Sellares J, Weir M and Loupy A. Real time central assessment of kidney transplant indication biopsies by microarrays: The INTERCOMEX Study. Am J Transplant 2017;17(11):2851-62.

12. **Halloran PF**, Potena L, Duong Van Huyen J-P., Bruneval P, Leone O, Kim DH, Jouven X, Reeve J and Loupy A. Building a tissue-based molecular diagnostic system in heart transplant rejection: the heart molecular microscope MMDx. J Heart Lung Transplant 2017;36(11):1192-200.

13. Reeve J, Bohmig GA, Eskandary F, Einecke G, Lefaucheur C, Loupy A, **Halloran PF** and the MMDx-Kidney study group. Assessing rejection-related disease in kidney transplant biopsies based on archetypal analysis of molecular phenotypes. JCI Insight 2017;2(12).

14. Reeve J and **Halloran PF**. Biopsy transcriptome expression profiling: proper validation is key. Lancet;389(10069):600-1.

15. Eskandary F, Bond G, Kozakowski N, Regele H, Marinova L, Wahrmann M, Kikic Z, Haslacher H, Rasoul-Rockenschaub S, Kaltenecker CC, Konig F, Hidalgo LG, Oberbauer R, **Halloran PF** and Bohmig GA. Diagnostic contribution of donor-specific antibody characteristics to uncover late silent antibody-mediated rejection-results of a cross-sectional screening study. Transplantation 2017;101(3):631-41.

16. Parkes MD, **Halloran PF** and Hidalgo LG. Mechanistic sharing between NK cells in ABMR and effector T cells in TCMR. Am J Transplant 2018;18(1):63-73.

17. Aubert O, Loupy A, Hidalgo L, Duong van Huyen JP, Higgins S, Viglietti D, Jouven X, Glotz D, Legendre C, Lefaucheur C and **Halloran PF**. Antibody-Mediated Rejection Due to Preexisting versus De Novo Donor-Specific Antibodies in Kidney Allograft Recipients. J Am Soc Nephrol;28(6):1912-23.

18. Eskandary F, Jilma B, Mulbacher J, Wahrmann M, Regele H, Kozakowski N, Firbas C, Panicker S, Parry GC, Gilbert JC, **Halloran PF** and Bohmig GA. Anti-C1s Monoclonal Antibody BIVV009 in Late Antibody-Mediated Kidney Allograft Rejection - Results from a First-in-Patient Phase 1 Trial. Am J Transplant 2018;18(4):916-26.

19. Eskandary F, Regele H, Baumann L, Bond G, Kozakowski N, Wahrmann M, et al. A Randomized, Placebo-Controlled Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection: The BORTEJECT Study. J Am Soc Nephrol 2018;29(2):591-605.

20. Einecke G, Reeve J, **Halloran PF**. A molecular biopsy test based on arteriolar under-hyalinosis reflects increased probability of rejection related to under-immunosuppression. Am J Transplant 2018;18(4):821-31.

21. **Halloran PF**, Venner JM, Madill-Thomsen K, Einecke G, Parkes MD, Hidalgo LG, et al. Review: The transcripts associated with organ allograft rejection. Am J Transplant 2018;18(4):785-95.

22. Eskandary F, Bond G, Kozakowski N, Regele H, Marinova L, Wahrmann M, et al. Diagnostic Contribution of Donor-Specific Antibody Characteristics to Uncover Late Silent Antibody-Mediated Rejection-Results of a Cross-Sectional Screening Study. Transplant 2017 Mar;101(3):631-41.

23. Loupy A, Hidalgo LG, Duong Van-Huyen JP, Jouven X, **Halloran PF**. Response by Loupy et al to Letters Regarding Article, "Gene Expresion Profiling for the Identification and Classification of Antibody-Mediated Heart Rejection". Circulation 2017;136(7):698-9.

24. Famulski KS, **Halloran PF**. Letter to AJT editor re: Nankivell. Am J Transplant 2018;18(3):765-66.

25. Haas M, Loupy A, Lefaucheur C, Roufousse C, Glotz D, Seron D, Nankivell BJ, **Halloran PF**, Colvin RB, Alachkar N, Bagnasco S, Bouatou Y, Becker JU, Cornell L, Duoung Van-Huyen JP, Gibson I, Mannon R, Naesens M, Nickeleit V, Nickerson P, Segev DL, Singh HK, Stegal M, Randhawa P, Racusen L, Solez K, Mengel M. The Banff 2017 Kidney Meeting Report: Revised Diagnostic Criteria for Chronic Active T Cell-Mediated Rejection, Antibody-Mediated Rejection, and Prospects for Integrative Endpoints for Next-Generation Clinical Trials. Am J Transplant 2018;18(2):293-307.

26. Arnold ML, Kainz A, Hidalgo LG, Eskandary F, Kozakowski N, Wahrmann M, Haslacher H, Oberbauer R, Heilos A, Spriewald BM, **Halloran PF** and Bohmig GA. Functional Fc gamma receptor gene polymorphisms and donor-specific antibody-triggered microcirculation inflammation. Am J Transplant 2018;18(9):2261-2273.

27. Kumar D, Yakubu I, Cooke RH, **Halloran PF**, Gupta G. Belatacept rescue for delayed kidney allograft function in a patient with previous combined heart-liver transplant. Am J Transplant 2018 Jul 7;18(10):2613-4.

28. **Halloran PF**, Aliabadi AZ, Bruneval P, Cadeiras M, Crespo-Leiro MG, Deng M, et al. Exploring the cardiac response-to-injury in heart transplant biopsies. JCI Insight 2018;3(20):12364.

29. **Halloran PF**, Matas A, Kasiske BL, Madill-Thomsen K, Mackova M and Famulski KS. Molecular phenotype of kidney transplant indication biopsies with inflammation in scarred areas. Am J Transplant 2019;19(5):1356-1370.

30. Halloran KM, Parkes MD, Chang J, Timofte IL, Snell GI, Westall GP, Hachem R, Kreisel D, Trulock E, Roux A, Juvet S, Keshavjee S, Jaksch P, Klepetko W and **Halloran PF**. Molecular Assessment of Rejection and Injury in Lung Transplant Biopsies. Journal of Heart and Lung Transplantation 2019;38(5):504-513.

31. Parkes MD, Aliabadi AZ, Cadeiras M, Crespo-Leiro MG, Deng M, Depasquale EC, Goekler J, Kim DH, Kobashigawa J, Loupy A, Macdonald P, Potena L, Zuckermann A and **Halloran PF**. An integrated molecular diagnostic report for heart transplant biopsies using an ensemble of diagnostic algorithms. Journal of Heart and Lung Transplantation 2019;38(6):636-646.

32. Reeve J, Bohmig GA, Eskandary F, Einecke G, Madill-Thomsen K, Mackova M, **Halloran PF** and the MMDx-Kidney Study Group. Generating automated kidney transplant biopsy reports using ensembles of molecular classifiers. Am J Transplant 2019. In press. <https://doi.org/10.1111/ajt.15351>

33. Bohmig GA, Eskandary F, Doberer K and **Halloran PF**. The therapeutic challenge of late antibody-mediated kidney allograft rejection. Transplant International 2018. In press.

<https://doi.org/10.1111/tri.13436>

34. Bohmig GA, Mezo B, Heilos A, Eskandary F, Wahrmann M, Bond G, et al. Complement Markers in Blood and Urine: No Diagnostic Value in Late Silent Antibody-Mediated Rejection. Transplantation Direct. 2019;5(7):e470.

35. Blanka M, Reindl-Schwaighofer R, Eskandary F, Heinzel A, Wahrmann M, Doberer K, Heilos A, Bond G, Kläger J, Kozakowski N, Haslacher H, Oberbauer R, Viklický O, Hrubá P, Halloran PF, Rusai K, Prohaszka Z, Böhmig GA. High-Activity Classical and Alternative Complement Pathway Genotypes – Impact on Donor-Specific Antibody-Triggered Injury and Renal Allograft Survival. JASN 2019. In press.

36. Halloran KM, Parkes MD, Timofte IL, Snell GI, Westall GP, Hachem R, Kreisel D, Levine D, Juvet S, Keshavjee S, Jaksch P, Klepetko W, Hirji A, Weinkauf J, and Halloran PF. Molecular phenotyping of rejection-related changes in mucosal biopsies from lung transplants. Am J Transplant 2019. In press.